Headshot of Lewis Cantley

Lewis Cantley, Ph.D.

Professor of Cell Biology (HMS)
Dana-Farber Cancer Institute
TBA--

Lew Cantley is widely known for his many seminal discoveries in signaling and metabolism, including the identification of PI3 kinase and its role in transformation, as well as groundbreaking work unraveling the complexities of protein kinase signaling--his work has had major impact across virtually every aspect of cancer cell biology. For those of you who are new to the department, Lew was a Cell Bio faculty member from 1992-2003 before transitioning to the then newly formed HMS Department of Systems Biology in 2003. In 2012, Lew was recruited to Weill Cornell in New York City, where he served as Director of the Meyer Cancer Center. There, he built a remarkable program focused on the intersection of metabolism and signaling in cancer.

Lew rejoined the Department of Cell Biology at HMS and the DFCI-Cancer Cell Biology in 2022.  

Dana Farber Cancer Institute

Cancer Cell Biology

Faculty Assistant

In-gel stable isotope labeling for relative quantification using mass spectrometry.
Authors: Authors: Asara JM, Zhang X, Zheng B, Maroney LA, Christofk HR, Wu N, Cantley LC.
Nat Protoc
View full abstract on Pubmed
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin.
Authors: Authors: Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, Montminy M, Cantley LC.
Science
View full abstract on Pubmed
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells.
Authors: Authors: Isakoff SJ, Engelman JA, Irie HY, Luo J, Brachmann SM, Pearline RV, Cantley LC, Brugge JS.
Cancer Res
View full abstract on Pubmed
Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess.
Authors: Authors: Barbour LA, Mizanoor Rahman S, Gurevich I, Leitner JW, Fischer SJ, Roper MD, Knotts TA, Vo Y, McCurdy CE, Yakar S, Leroith D, Kahn CR, Cantley LC, Friedman JE, Draznin B.
J Biol Chem
View full abstract on Pubmed
Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy.
Authors: Authors: Luo J, McMullen JR, Sobkiw CL, Zhang L, Dorfman AL, Sherwood MC, Logsdon MN, Horner JW, DePinho RA, Izumo S, Cantley LC.
Mol Cell Biol
View full abstract on Pubmed
The negative regulation of phosphoinositide 3-kinase signaling by p85 and it's implication in cancer.
Authors: Authors: Luo J, Cantley LC.
Cell Cycle
View full abstract on Pubmed
Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.
Authors: Authors: Keilhack H, David FS, McGregor M, Cantley LC, Neel BG.
J Biol Chem
View full abstract on Pubmed
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Authors: Authors: Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.
J Natl Cancer Inst
View full abstract on Pubmed
PtdIns(4,5)P2 functions at the cleavage furrow during cytokinesis.
Authors: Authors: Field SJ, Madson N, Kerr ML, Galbraith KA, Kennedy CE, Tahiliani M, Wilkins A, Cantley LC.
Curr Biol
View full abstract on Pubmed
The p85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex.
Authors: Authors: Luo J, Field SJ, Lee JY, Engelman JA, Cantley LC.
J Cell Biol
View full abstract on Pubmed